Veeva Systems serves as the primary cloud software provider for the life sciences sector, supporting pharmaceutical and biotechnology firms with tools for clinical, regulatory, quality, and commercial functions. Its quarterly updates serve as a useful gauge of technology spending trends throughout the drug development space. The company has delivered consistent outperformance, with revenue climbing 18% year over year to roughly $928 million and adjusted earnings per share reaching $2.35 in the fiscal second quarter. That result, paired with an increase to full-year guidance, has raised the stakes for the upcoming report. As Veeva rolls out more AI-driven offerings, this update should provide insight into both immediate demand and the company's longer-term trajectory.
Analysts are looking for revenue of about $935 million in the fiscal 2027 third quarter, implying roughly 15% year-over-year growth from the $811 million posted a year earlier. Consensus calls for adjusted earnings per share of approximately $2.34, compared with $2.04 in the same period last year. These projections line up closely with the company's guidance range of $932 million to $935 million in revenue and $2.33 to $2.34 in non-GAAP earnings per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Non-GAAP figures strip out items such as stock-based compensation to better reflect underlying operations. In the fiscal second quarter, Veeva posted non-GAAP earnings per share of $2.35 against a consensus estimate near $2.23, with revenue of $927.96 million. The company has surpassed consensus earnings estimates in seven of the past eight quarters. Beyond the top-line figures, investors will focus on subscription revenue trends in both the Commercial and R&D segments, along with any revisions to full-year fiscal 2027 guidance, which currently targets non-GAAP earnings per share of about $9.21 on revenue of $3.682 billion to $3.687 billion.
Investor tone ahead of the report remains generally positive, supported by Veeva's steady performance and its central role in the AI-driven evolution of life sciences software. Coverage from firms including Barclays and RBC Capital stays constructive, with Buy ratings and price targets of $375 and $365 set in early November, while Morgan Stanley maintains a Hold stance. The stock has tended to respond favorably to recent beats. That said, high expectations mean any shortfall in subscription growth, pressure on margins, or tempered outlook could pressure the shares. I’m watching this closely for early signs that newer AI offerings are converting interest into actual revenue.
Once the numbers are out, attention will turn to several forward indicators. Updated full-year fiscal 2027 guidance, and any initial thoughts on fiscal 2028, will likely shape the market's reaction. Commentary around the commercialization of AI products such as Veeva Falcon will also matter, given that meaningful revenue from these initiatives is still emerging. Progress on the shift in the R&D portfolio from legacy products to newer platforms like EDC and LIMS will influence growth patterns. Finally, margin trends and operating leverage remain important, as any additional investment commentary tied to AI and new products could affect perceptions of future profitability.
When preparing for reports like this one, I often rely on Tickeron’s AI Screener to quickly compare VEEV against industry peers and spot relevant technical or fundamental signals. The tool lets me apply customizable filters across thousands of stocks and ETFs, helping surface comparable ideas and monitor market shifts without manual effort. It has become a regular part of how I cross-check data points and refine focus areas ahead of earnings.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VEEV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 54 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 69%.
The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 133 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry